News | October 20, 2014

Boston Scientific Initiates Study Of Promus Premier Coronary Stent in Underserved Patient Populations

Study will enroll up to 1,500 patients at 65 sites to help doctors provide evidence-based treatment

October 20, 2014 — Boston Scientific Corp. has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color. The Promus Premier stent system is the company's latest durable polymer drug-eluting stent (DES) and is approved by the U.S. Food and Drug Administration (FDA) to treat coronary artery disease. Wayne Batchelor, M.D., FACC, FSCAI, and co-principal investigator, enrolled the first patient in the PLATINUM Diversity trial at Tallahassee Memorial Hospital, in Tallahassee, Fla. 

Historically, large-scale clinical trials in cardiology have had a disproportionately low inclusion of women and non-white patients. As a result, physicians have had little data on which to base their clinical decisions when treating these patients. The PLATINUM Diversity trial is aligned with recent actions taken by the FDA, including implementation of FDASIA 907: Inclusion of Demographic Subgroups in Clinical Trials, and with the Boston Scientific “Close the Gap” education initiative, which aims to promote health equity and ensure all patients receive optimal health care regardless of age, gender, race, ethnicity or primary language. 

"Creating a treatment plan specifically tailored to underrepresented populations has long been a challenge in clinical practice due to the lack of specific outcomes data from cardiovascular clinical trials," said Roxana Mehran, M.D., director of interventional cardiovascular research and clinical trials at Icahn School of Medicine at Mount Sinai Medical Center and principal investigator. "I am excited to be part of a trial that aims to fill the data demographic gap in the stent space and provides physicians with additional knowledge to make the best treatment decisions possible for their patients."

The PLATINUM Diversity trial is an observational, prospective, multicenter, open-label, single-arm, post-approval study that will enroll up to 1,500 patients from understudied populations — specifically women, black Americans, Latinos/Hispanics, American Indians or Alaska Natives — at up to 65 sites in the United States. The primary study endpoint is the rate of the composite of death, myocardial infarction and target vessel revascularization through 12 months. Initial data are expected to be available in 2016.

"The number of minority and female patients participating in clinical trials is often not representative of disease epidemiology," said Batchelor. "Since different populations may respond differently to various therapies, it is important that we generate data to help clinicians make evidence-based treatment decisions for all patients."

According to the U.S. Centers for Disease Control and Prevention, cardiovascular disease is the leading cause of death for all Americans, including women and minorities. Despite this reality, women represent less than one-third of those in cardiovascular trials conducted since 2006; black Americans represent about 12 percent of the United States’ population, yet they comprise just five percent of patients in clinical trials.

"We know that more women are dying from heart disease than any other cause.  WomenHeart is advocating that the FDA implement strategies to ensure appropriate representation of women in clinical research and that results from trials be analyzed, reported by sex and easily accessible," said Lisa M. Tate, chief executive officer of WomenHeart: The National Coalition for Women with Heart Disease. "Doctors and patients can't assess which treatment is best if meaningful data for women are not available."

For more information: www.bostonscientific.com

 

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init